Butobarbital, also called butobarbitone or butethal, Soneryl, and Neonal,[1] is a hypnotic drug which is a barbiturate derivative.[2] It was developed by Poulenc Brothers (now part of Sanofi) in 1921.[3]
Clinical data | |
---|---|
Trade names | Soneryl |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Liver |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.928 |
Chemical and physical data | |
Formula | C10H16N2O3 |
Molar mass | 212.249 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
edit- ^ International Drug Names
- ^ Nordegren T (2002). "Butobarbital". The A-Z encyclopedia of alcohol and drug abuse. Parkland, Fla.: Brown Walker Press. p. 144. ISBN 978-1-58112-404-0.
- ^ DE 481129, "Verfahren zur Herstellung von n-Butylaethylbarbitursaeure", published 3 February 1922, issued 14 August 1929, assigned to ETS Poulenc Freres.